Tag: Selective norepinephrine reuptake inhibitor

  • Atomoxetine

    Selective norepinephrine reuptake inhibitor

    A selective NRI FDA-approved as Strattera for ADHD, the first non-stimulant FDA-approved for the indication.

    Abstract

    Atomoxetine (Strattera; CAS 83015-26-3; molecular formula C17H21NO; molecular weight 255.36) is a selective norepinephrine reuptake inhibitor (NRI) developed by Eli Lilly and approved by the FDA in 2002 for ADHD in children, adolescents, and adults. The compound is the first non-stimulant FDA-approved for ADHD. Mechanism is NET inhibition; the compound is essentially inactive at DAT and SERT. Pharmacokinetics: plasma half-life 5.2 hours in extensive metabolizers via CYP2D6, 21.6 hours in poor metabolizers; doses are titrated based on response and tolerability. Schedule status: not scheduled (distinguishing it from amphetamine and methylphenidate ADHD therapies).

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Reboxetine

    Selective norepinephrine reuptake inhibitor

    A selective NRI marketed in Europe as Edronax for depression but rejected by the FDA for inadequate efficacy.

    Abstract

    Reboxetine (Edronax; CAS 71620-89-8; molecular formula C19H23NO3; molecular weight 313.39) is a selective norepinephrine reuptake inhibitor approved in Europe (1997) for major depressive disorder. The FDA rejected the compound’s NDA for inadequate efficacy demonstration. The compound is marketed as the racemate; the (S,S)-enantiomer carries the majority of NET inhibition activity. Pharmacokinetics: plasma half-life 13 hours. The compound is sold as a research chemical in jurisdictions where it is not specifically scheduled.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.